Myeloid Therapeutics Doses First Patient with MT-101 in the IMAGINE Phase I/II Clinical Study, Marking the First-ever Dosing of an mRNA Engineered CAR Monocyte to Humans

Myeloid Therapeutics, Inc. announced the first patient dosed in the IMAGINE Study, a Phase I/II clinical study of MT-101, the first mRNA engineered CAR monocyte derived from the Company’s proprietary ATAK™ platform, in patients with refractory or relapsed peripheral T cell lymphoma, an aggressive form of non-Hodgkin lymphoma.